Mr. J. Roderick Matheson reports

MARVEL BIOSCIENCES SELECTS NOVOTECH AS CRO FOR ITS PHASE I CLINICAL TRIAL OF MB-204

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., have selected Novotech as the contract research organization (CRO) for the company's coming phase I for its lead drug candidate, MB-204. Novotech is an internationally recognized full-service CRO based in Australia that was awarded the 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan in recognition of its innovation, client-focused delivery and global impact.

"Having previously worked with Novotech on multiple clinical programs, I am pleased to be working with Novotech again," said Dr. Mark Williams, chief scientific officer of Marvel Biosciences. "Australia is an attractive place to conduct first-in-man studies owing to their favourable regulatory environment and tax credits exceeding 40 per cent of the costs incurred there."

MB-204 is Marvel's patented neuroactive adenosine A2A antagonist that has completed cGMP (current good manufacturing practice) synthesis and four-week GLP (good laboratory practice) toxicological studies. MB-204 is being developed for neurodevelopmental disorders such as Rett syndrome and fragile X, with the potential to treat autism spectrum disorder and depression. Selecting a leading Australian CRO positions Marvel Biosciences to accelerate its phase I program through a streamlined regulatory pathway with significant cost-efficiencies, maximizing capital while maintaining world-class clinical standards. Partnering with Novotech marks a pivotal inflection point for the company, signalling MB-204's transition into human trials and reinforcing confidence in its potential to deliver value in underserved neurodevelopmental indications.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary, Marvel Biotechnology, is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. The company's lead drug candidate, MB-204, is a novel fluorinated derivative version of istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and fragile X syndrome, aiming to bring new options to patients with few effective treatments.